Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis
Background Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers. We performed this meta-analysis to illustrate the preliminary predictive value of TSP-1.
Methods Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis.
Results A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival (OS) (HR=1.40, 95% CI: 1.17~1.68; P<0.001). However, high TSP-1 expression predicted no significant impact on progression-free survival (PFS)/ metastasis-free survival (MFS) (HR=1.35, 95%CI: 0.87-2.10; P=0.176) and disease-free survival (DFS)/ recurrence-free survival (RFS) (HR = 1.40, 95%CI: 0.77–2.53; P=0.271). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Additionally, the relatively small number of studies on PFS/MFS and DFS/RFS is a limitation. The data extracted through Kaplan-Meier curves may not be accurate. Moreover, only English articles were included in this article, which may lead to deviations in the results.
Conclusions Our findings indicated high TSP-1 expression may act as a promising biomarker of poor prognosis in cancers, especially in breast cancer and gynecological cancer.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Posted 19 Jun, 2020
On 29 Jun, 2020
On 18 Jun, 2020
On 18 Jun, 2020
On 05 Jun, 2020
Received 04 Jun, 2020
On 03 Jun, 2020
Received 03 Jun, 2020
Invitations sent on 02 Jun, 2020
On 02 Jun, 2020
On 01 Jun, 2020
On 31 May, 2020
On 31 May, 2020
Received 18 May, 2020
On 18 May, 2020
On 30 Apr, 2020
Received 26 Apr, 2020
On 11 Apr, 2020
Invitations sent on 06 Apr, 2020
On 17 Mar, 2020
On 16 Mar, 2020
On 16 Mar, 2020
On 13 Mar, 2020
Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis
Posted 19 Jun, 2020
On 29 Jun, 2020
On 18 Jun, 2020
On 18 Jun, 2020
On 05 Jun, 2020
Received 04 Jun, 2020
On 03 Jun, 2020
Received 03 Jun, 2020
Invitations sent on 02 Jun, 2020
On 02 Jun, 2020
On 01 Jun, 2020
On 31 May, 2020
On 31 May, 2020
Received 18 May, 2020
On 18 May, 2020
On 30 Apr, 2020
Received 26 Apr, 2020
On 11 Apr, 2020
Invitations sent on 06 Apr, 2020
On 17 Mar, 2020
On 16 Mar, 2020
On 16 Mar, 2020
On 13 Mar, 2020
Background Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers. We performed this meta-analysis to illustrate the preliminary predictive value of TSP-1.
Methods Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis.
Results A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival (OS) (HR=1.40, 95% CI: 1.17~1.68; P<0.001). However, high TSP-1 expression predicted no significant impact on progression-free survival (PFS)/ metastasis-free survival (MFS) (HR=1.35, 95%CI: 0.87-2.10; P=0.176) and disease-free survival (DFS)/ recurrence-free survival (RFS) (HR = 1.40, 95%CI: 0.77–2.53; P=0.271). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Additionally, the relatively small number of studies on PFS/MFS and DFS/RFS is a limitation. The data extracted through Kaplan-Meier curves may not be accurate. Moreover, only English articles were included in this article, which may lead to deviations in the results.
Conclusions Our findings indicated high TSP-1 expression may act as a promising biomarker of poor prognosis in cancers, especially in breast cancer and gynecological cancer.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6